Last updated July 15, 2026
Key finding
Telomere length increased by 0.06 (95% CI: 0.02, 0.11)
This study investigated the anti-aging effects of Henagliflozin in patients with Type 2 diabetes, finding an increase in telomere length and other biomarkers.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the anti-aging effects of Henagliflozin in patients with Type 2 diabetes, finding an increase in telomere length and other biomarkers.
The findings suggest that Henagliflozin could have broader implications beyond glucose control in Type 2 diabetes, potentially influencing aging processes and overall health. This could lead to new therapeutic strategies aimed at improving longevity and quality of life for individuals with diabetes.
Unclear effectiveness for some outcomes due to lack of specific p-values. Limited generalizability due to the specific population studied. Potential confounding factors not measured.
Published in
Publication details and source links for this paper.
Jie Z, Wei C, Danfeng L, et al. Henagliflozin Exerts Anti-Aging Effects in Patients with Type 2 Diabetes: A Randomized Trial. Cell Reports Medicine. 2025;6(9):102331. doi:10.1016/j.xcrm.2025.102331
Telomere length increased by 0.06 units (95% CI: 0.02, 0.11)
Insulin-like growth factor-binding protein-3 levels increased.
Beta-hydroxybutyrate levels increased.
Granzyme B expression in cytotoxic T lymphocytes increased.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Henagliflozin and Granzyme B expression in cytotoxic T lymphocytes increased, Increased Thiamine Levels, Insulin-like growth factor-binding protein-3 levels, and 4 more.
This study contributes evidence to
Primary intervention
Henagliflozin
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
7
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Henagliflozin → Granzyme B expression in cytotoxic T lymphocytes increased
Henagliflozin → Granzyme B expression in cytotoxic T lymphocytes increased
Henagliflozin → Increased Thiamine Levels
Henagliflozin → Increased Thiamine Levels
Henagliflozin → Insulin-like growth factor-binding protein-3 levels
Henagliflozin → Insulin-like growth factor-binding protein-3 levels
Henagliflozin → Perforin expression in cytotoxic T lymphocytes
Henagliflozin → Perforin expression in cytotoxic T lymphocytes
Henagliflozin → Perforin expression in total T lymphocytes
Henagliflozin → Perforin expression in total T lymphocytes
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Henagliflozin and Granzyme B expression in cytotoxic T lymphocytes increased, Henagliflozin and α-hydroxybutyrate.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Granzyme B expression in cytotoxic T lymphocytes increased
Measures Granzyme B expression in cytotoxic T lymphocytes increased as a key outcome.
All studies on Henagliflozin
Contributes to Henagliflozin evidence base.
All studies measuring α-hydroxybutyrate
Measures α-hydroxybutyrate as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Henagliflozin appears to improve Granzyme B expression in cytotoxic T lymphocytes increased.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Granzyme B expression in cytotoxic T lymphocytes increased
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Henagliflozin appears to improve Increased Thiamine Levels.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Increased Thiamine Levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Henagliflozin appears to improve Insulin-like growth factor-binding protein-3 levels.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Insulin-like growth factor-binding protein-3 levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Henagliflozin appears to improve Telomere length change.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Telomere length change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
